TM-38837

TM-38837 is a small molecule inverse agonist/antagonist of the CB₁ cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.^[1] The company has announced phase I clinical trials.

CAS Number

• 1034264-77-1

PubChem CID

• 66772777

CompTox Dashboard (EPA)

• DTXSID301018782

FormulaC₂₇H₂₀Cl₂F₃N₇O

Quick facts Identifiers, CAS Number ...

TM-38837

Identifiers
IUPAC name 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2H-tetrazol-5-ylmethyl)-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide
CAS Number	1034264-77-1
PubChem CID	66772777
CompTox Dashboard (EPA)	DTXSID301018782
Chemical and physical data
Formula	C27H20Cl2F3N7O
Molar mass	586.40 g·mol−1
3D model (JSmol)	Interactive image
SMILES ClC(C=C1)=C(C=C1)N(N=C1C(=O)N[C@H](C)C(C=CC2C(F)(F)F)=CC=2)C(=C1CC(N=N1)=NN1)C(C=CC1Cl)=CC=1
InChI InChI=1S/C27H20Cl2F3N7O/c1-15(16-6-10-18(11-7-16)27(30,31)32)33-26(40)24-20(14-23-34-37-38-35-23)25(17-8-12-19(28)13-9-17)39(36-24)22-5-3-2-4-21(22)29/h2-13,15H,14H2,1H3,(H,33,40)(H,34,35,37,38)/t15-/m1/s1 Key:DANBLBWVACCFGQ-OAHLLOKOSA-N

Close

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB₁ receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference ^[2] but is now known from a more recent reference.^[3]